anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A resin-drug compound comprises a derivative of 2-aminopropan-1-one of formula <FORM:0928304/IV(a)/1> wherein R1 and R2 are C1 to C4 alkyl and R3 is phenyl or substituted phenyl, said derivative being adsorbed in ion-exchange relationship on a cation exchange resin. The preferred derivative is 1-phenyl-2-diethylaminopropan-1-one (otherwise called diethylpropion), and the resin may be sulphonated, cross-linked polystyrene or cross-linked polymethacrylic acid.  The products find application in pharmaceutical preparations for appetite depressant purposes.ALSO:A pharmaceutical or veterinary composition having appetite depressant activity, comprises a resin-drug compound of a 2-aminopropan-1-one of formula <FORM:0928304/VI/1> wherein R1 and R2 are C1 to C4 alkyl and R3 is phenyl or substituted phenyl, adsorbed in ion-exchange relationship on a cation exchange resin. The preferred resin-drug compounds are derived from 1-phenyl-2-diethyl-aminopropan-1-one and sulphonated, cross-linked polystyrene or cross-linked polymethacrylic acid.  The compositions may be in forms for oral administration, e.g. tablets, pills, capsules, powders, granules, syrups, emulsions and dispersions, such forms comprising conventional pharmaceutical excipients and optionally other therapeutic agents as may improve the reduction of the undesirable side effects of the 2-aminopropan-1-one compound.  An example also describes a suppository.
Electroacupuncture group treatment: After the above acupuncture to deqi, choose KWD-808 Ⅰ type Indy brand pulse acupuncture treatment instrument, the waveform is continuous wave, the stimulation frequency is 2Hz, the intensity to be tolerated by the patient. There should be muscle contraction at the acupuncture site during electroacupuncture treatment. The treatment time should be 30 minutes each time, once a day, 6 days a week with 1 day off, for a total of 3 weeks.
A modular energy system includes modules, at least two having a transceiver timer. The modules communicate data messages over an internal bus. A first module obtains a transmission time from its transceiver timer, which it appends to the message, and transmits the appended message over the internal data bus. The second module receives the data message, obtains a receipt time from its transceiver timer, and extracts the transmission time from the message. A smart surgical system includes a plurality of surgical subsystems including a modular energy system all in mutual data communication over a system data bus. The components of the smart surgical system may each have a transceiver timer. The components of the smart surgical system transmit and receive data across the system data bus using the respective transceiver timers in a manner like the communications between the modular energy system modules.
PURPOSE: A composition using Stichopus japonicus Orange extract is provided to suppress generation of NO(nitric oxide), inflammatory cytokines such as TNF-alpha and IL-6, COS-2(clooxygenase-2). CONSTITUTION: An anti-inflammatory composition contains Stichopus japonicus Orange extract as an active ingredient. The Stichopus japonicus Orange extract is isolated using alcohol of 1-5 carbon atoms, acetone, ethylacetate, ether, methylene chloride, chloroform, n-alkane of 5-10 carbon atoms, or mixture thereof. A composition of iNOS inhibition contains the Stichopus japonicus Orange extract as an active ingredient. A composition of COX-2 inhibition contains the Stichopus japonicus Orange extract as an active ingredient. An anti-cancer composition contains the Stichopus japonicus Orange extract as an active ingredient. The composition is a pharmaceutical composition or food composition.
PURPOSE OF REVIEW: Although there have been advancements in minimally invasive surgical techniques for radical prostatectomy, surgery can still significantly impact continence and erectile function (EF), resulting in considerable quality-of-life impairment. This review critically evaluates existing treatment options for male stress urinary incontinence (SUI) and erectile dysfunction (ED) post-robotic-assisted laparoscopic prostatectomy (RALP), alongside exploring emerging trends and discussing future directions for managing and preventing both conditions.
RECENT FINDINGS: Patient history is pivotal in guiding surgical decisions, with the intensity of symptoms and their impact on the patient's life being primary influences for deciding the best treatment options for both SUI and ED. Penile rehabilitation strategies (PR) show promise in mitigating the effects of prostate cancer treatments on EF and improving overall health, though consensus is lacking on specific programs or initiation of timing for optimal recovery post-surgery. All patients undergoing RALP should receive preoperative counseling about SUI and early pelvic floor physical therapy. Fixed and adjustable slings effectively treat mild-to-moderate post-RALP SUI, while the artificial urinary sphincter is the gold standard for men with moderate or severe SUI. EF recovery after RALP faces obstacles such as patient characteristics, compliance, and cost, with no standardized PR approach. Future research should prioritize studies aiming to optimize treatment methods and enhance patient compliance.
BACKGROUND/AIMS: Early studies on direct oral anticoagulants (DOACs) reported a higher risk of gastrointestinal bleeding (GIB) compared with warfarin; however, recent studies have reported a reduced risk. Therefore, this study was designed to evaluate the risk of GIB in users of DOAC and warfarin.
METHODS: Using a common data model, we investigated the comparative risk of GIB in subjects from eight hospitals who were newly prescribed DOACs or warfarin. We excluded subjects who had a prior history of GIB or had been prescribed both medications. After propensity score matching, we analyzed 3,347 matched pairs of new DOAC and new warfarin users.
RESULTS: The risk of GIB in new DOAC users was comparable to that in new warfarin users (hazard ratio [HR], 0.95; 95% confidence interval [CI], 0.65 to 1.40; p=0.808). New DOAC users had a similar risk of GIB to new warfarin users among older patients >65 years (HR, 1.00; 95% CI, 0.69 to 1.52; p=0.997) and in older patients >75 years (HR, 1.21; 95% CI, 0.68 to 2.10; p=0.509). In addition, the risk of GIB was not significantly different between two groups according to sex. We also found that the risk of GIB in DOAC users was 26% lower in edoxaban or apixaban subgroups compared to rivaroxaban or dabigatran subgroups (HR, 0.74; 95% CI, 0.69 to 1.00; p=0.049).
CONCLUSIONS: In real-world practice, the risk of GIB in new DOAC users is comparable to that in new warfarin users. In DOAC users, the risk of GIB was lower in edoxaban or apixaban subgroups than rivaroxaban or dabigatran subgroups.
BACKGROUND: Enterococcus casseliflavus is a rare pathogenic bacterium that is characterized by vancomycin resistance and can lead to multiple infections in the human body. This report describes a rare case of polycystic intrahepatic infection with E. casseliflavus which necessitated antibiotic treatment and surgical intervention involving cystic drainage.
CASE PRESENTATION: A 59-year-old woman, a long-term hemodialysis patient, was hospitalized due to a 5-day history of fever, abdominal pain, and diarrhea, which were possibly caused by the ingestion of contaminated food. Her blood culture yielded a positive result for E. casseliflavus, and she was initially treated with piperacillin/tazobactam and linezolid. Later, the antibiotic regimen was adjusted to include meropenem and linezolid. Despite treatment, her body temperature remained elevated. However, subsequent blood cultures were negative for E.casseliflavus.Conventional CT scans and ultrasound examinations did not identify the source of infection. However, a PET-CT examination indicated an intrahepatic cyst infection. Following MRI and ultrasound localization, percutaneous intrahepatic puncture and drainage were performed on the 20th day. Fluoroquinolones were administered for 48 days. On the 32nd day, MRI revealed a separation within the infected cyst, leading to a repeat percutaneous drainage at a different site. Subsequently, the patient's temperature returned to normal. The infection was considered resolved, and she was discharged on the 62nd day. Follow-up results have been favorable thus far.
CONCLUSIONS: Based on the findings from this case, it is recommended to promptly conduct PET-CT examination to exclude the possibility of intracystic infection in cases of polycystic liver infection that are challenging to control. Furthermore, timely consideration should be given to puncture drainage in difficult cases.
Based on the treatment protocol for this study the patients will receive the henna treatment for 4 weeks (supervised treatment for first week and then unsupervised sessions twice a week). The treatment will include the application of the henna mixture (paste) (40gr natural henna and 40ml of purified water) to the affected areas (feet or/and hands) and wear socks or/and gloves. The treatment session will last for 1 hour and then the mixture will be rinsed with fresh water.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Estradiol transdermal system was investigated in a 2-year double blind, placebo-controlled, multicenter study in the United States. A total of 417 postmenopausal women (208 women on estradiol transdermal system, 209 on placebo) 60 to 80 years old, with an intact uterus were enrolled in the study. At 24 months, 189 women remained in the estradiol transdermal system group and 186 remained in the placebo group. Adverse events with an incidence of ≥5 percent in the estradiol transdermal system 0.014 mg group and greater than those reported in the placebo group are listed in Table 1.

Table 1

Summary of Most Frequently Reported Treatment Emergent Adverse Reactions (≥5 percent) by Treatment Groups
These injections will target the deep para-spinal muscles between the spinous process and inter-pedicular line of the L3-5 vertebrae. Under fluoroscopic guidance, a 25-gauge needle will be advanced, directed towards the lamina at the mid-distance between inter-pedicular line and the spinous process of the L3, L4 and L5 vertebrae, until touching the bone. A straight forceps will be attached to the junction of the skin and the needle; the needle will then be withdrawn by 1.4cm, to reside inside the muscle bulk. A five ml syringe diameter will be used to point 1.4 cm withdrawal. Following a negative blood aspiration, each level will be injected with 0.5 ml of the injectate.
PCT No. PCT/EP94/01614 Sec. 371 Date Mar. 28, 1996 Sec. 102(e) Date Mar. 28, 1996 PCT Filed May 19, 1994 PCT Pub. No. WO94/27886 PCT Pub. Date Dec. 8, 1994The invention provides a package for accommodating product having at least two components, which package has at least two self-contained chambers in which the individual components of the product can be stored in such a manner that they are hermetically separated from one another. The end regions of the chamber walls are in the form of a common closure for the individual chambers such the individual chambers can only be opened simultaneously.
Rheumatoid arthritis (RA) is an autoimmune disease featured by chronic synovitis and progressive joint damage. Early treatment before the onset of clinical symptoms (also known as the pre-RA stage) may slow or stop the progression of the disease. We sought to discover the dynamic metabolic changes during the evolution of collagen-induced arthritis (CIA) to better characterize the disease stages. Untargeted metabolomics analysis using gas chromatography-mass spectrometry revealed that the metabolic profiles of CIA mice gradually differed from that of the control group with the progression of the disease. During the induction phase, the CIA group showed some metabolic alterations in galactose metabolism, arginine biosynthesis, tricarboxylic acid cycle (TCA cycle), pyruvate metabolism, and starch/sucrose metabolism. During the early inflammatory phase, no joint swelling was observed in CIA mice, and metabolites changed mainly involving amino acid metabolism (arginine biosynthesis, arginine/proline metabolism, phenylalanine/tyrosine/tryptophan biosynthesis), and glutathione metabolism. During the peak inflammatory phase, severe arthritis symptoms were observed in CIA mice, and there were more extensive metabolic alterations in valine/leucine/isoleucine biosynthesis, phenylalanine/tyrosine/tryptophan biosynthesis, TCA cycle, galactose metabolism, and arginine biosynthesis. Moreover, the reduction of specific amino acids, such as glycine, serine, and proline, during the early stages may result in an imbalance in macrophage polarization and enhance the inflammatory response in CIA mice. Our study confirmed that specific perturbations in amino acid metabolism have occurred in CIA mice prior to the onset of joint symptoms, which may be related to autoimmune disorders. The findings could provide insights into the metabolic mechanism and the diagnosis of pre-RA.
A method for improving intracellular translational efficiency and/or stability of RNA molecules. An RNA molecule preparation method is provided, comprising a step of adding a modified poly (A) sequence composed of a modified adenylic acid and an optional unmodified adenylic acid at the 3' end of the poly (A) tail of a starting RNA molecule. The RNA molecule may be an mRNA molecule. Also provided are an RNA molecule, a pharmaceutical composition, a corresponding use, and a kit. The poly (A) tail of the RNA molecule prepared by the method is extended and has a modified adenylic acid at the extended portion. Compared with a starting RNA molecule without an extended poly (A) tail or an RNA molecule with an extended poly(A) tail that does not contain a modified adenylic acid, the present RNA molecule has improved intracellular translational efficiency and/or stability.
Fentanyl buccal tablets are supplied in individually sealed, child-resistant blister packages. Each carton contains 7 blister cards with 4 white tablets in each card. The blisters are child-resistant, encased in peelable foil, and provide protection from moisture. Each tablet is debossed on one side with , and the other side of each dosage strength is uniquely identified by the debossing on the tablet as described in the table below. In addition, the dosage strength is indicated on the blister package and the carton. See blister package and carton for product information.

Note: Carton/blister package colors are a secondary aid in product identification. Please be sure to confirm the printed dosage before dispensing.

Storage and Handling

Store at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C and 30°C (59°F to 86°F) until ready to use. (See USP Controlled Room Temperature.)

Protect fentanyl buccal tablet from freezing and moisture. Do not use if the blister package has been tampered with.

Store fentanyl buccal tablet securely and dispose of properly.
A method and system for generating advisory messages to pharmacy patients includes appending patient-specific information to a data record containing normally transmitted information. The data record is transmitted between a third party computer and a pharmacy computer during a pharmacy transaction.  The data record transmitted to the pharmacy computer is captured by an advisory computer as the data record is received by the pharmacy computer or after the data record is transmitted to the pharmacy computer, and the patient-specific information is extracted from the captured data record. The advisory computer generates an advisory message based on the extracted patient-specific information, and it transmits the generated advisory message to a pharmacy printer. The advisory computer includes a memory containing a data structure for storing the patient-specific information, the normally transmitted information, and the generated advisory message. A computer program product includes a computer storage medium and a computer program code mechanism embedded in the computer storage medium for causing a computer to generate an advisory message. The computer program code mechanism includes a first computer code device configured to append the patient-specific information, a second computer code device configured to capture the data record transmitted to the pharmacy computer, a third computer code devise configured to extract the patient-specific information from the captured data record, a fourth computer code device configured to generate the advisory message based on the extracted patient specific information, and a fifth computer code device configured to transmit the generated advisory message to the pharmacy printer.
In the Mes-G group, all surgeries were performed by one surgeon team (J.K.) from January 2013 using the following strategy for the proximal division site: the diseased bowel and para-intestinal mesentery were carefully compared by palpation and translucent observation through a shadowless lamp. The comparison was conducted from the diseased bowel towards the normal-appearing region upstream, to identify a point where the hypertrophied mesentery transitioned into normal thickness and softness and became translucent as observed through the shadowless lamp.
In Trial 321, 87 treatment-experienced subjects 12 years to less than 18 years of age were treated with VIREAD (N=45) or placebo (N=42) in combination with an optimized background regimen (OBR) for 48 weeks. The mean baseline CD4 cell count was 374 cells/mm3 and the mean baseline plasma HIV-1 RNA was 4.6 log10 copies/mL. At baseline, 90% of subjects harbored NRTI resistance-associated substitutions in their HIV-1 isolates. Overall, the trial failed to show a difference in virologic response between the VIREAD and placebo groups. Subgroup analyses suggest the lack of difference in virologic response may be attributable to imbalances between treatment arms in baseline viral susceptibility to VIREAD and OBR.

Although changes in HIV-1 RNA in these highly treatment-experienced subjects were less than anticipated, the comparability of the pharmacokinetic and safety data to that observed in adults supports the use of VIREAD in pediatric patients 12 years and older who weigh at least 35 kg and whose HIV-1 isolate is expected to be sensitive to VIREAD [see Warnings and Precautions (5.5), Adverse Reactions (6.1), and Clinical Pharmacology (12.3)].
PURPOSE: To obtain an antacid product comprising an antacid active compound, polycarbophil calcium salt and water-insoluble anionic polymer, having high adhesivity to the gastric mucosa and extended passage time through the stomach. CONSTITUTION: This antacid product comprises an antacid active compound agglomerated with calcium polycarbophil (i.e., calcium salt derived from divinyl alcohol and crosslinked polyacrylic acid) by use of a water-insoluble anionic polymer as binder (e.g. polyacrylic acid/methacrylate copolymer, cellulose acetate phthalate, shellac), wherein the antacid active compound is pref. an aluminum- and/or magnesium-contg. compound, esp. pref. aluminum plus magnesium-contg. antacid active substance with lamellar lattice structure (e.g. hydrotalcite, magaldrate, almagate).
After a stroke, a wide range of neurological disorders can occur. One of them is impairments of the visual-oculomotor system in 8-31% of cases. Such patients experience loss of visual fields, hemianopia, tunnel vision, diplopia. All this causes great difficulties for returning to everyday life, as well as to professional activity. The eye tracking method allows to diagnose and evaluate the effectiveness of training aimed at improving the functioning of the saccadic system, reducing the volume of visual deficit. Currently, eye tracking is represented by a variety of technological solutions, but not all of them are used in the clinic.

The aim of the study is the application of an eye tracking-based device in cerebral stroke survivors for the correction of oculomotor disorders and visual attention functions.

Stroke patients participate in the study in Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency, Moscow, Russia. The study has been conducted since January, 10 and was approved by a local ethic committee and followed principles of the Declaration of Helsinki. The patients stay in a 24-hour hospital and undergo a rehabilitation course. For 3 weeks, patients receive daily training on the C-Eye Pro device, AssisTech Sp. z. o. o, Poland. The patients interact with the device only by using eye movements. Participants undergo a primary assessment of cognitive functions (memory, thinking skills, language, visual-spatial and communicative functions). According to the results of the diagnosis, participants are offered a scheme of correctional training and secondary assessment at the end of the training. Correction training consists, firstly, of 10-minute exercise at the beginning of each session, aimed at improving visual functions and attention. Patients have to follow the spontaneously moving object. The result is evaluated qualitatively using heat and scanpath maps. Secondly, the correctional training includes a block of neurorehabilitation (simple cognitive exercises similar to the tasks presented in assessment).
The present invention refers to a potent inhibitor of the transforming growth factor beta (TGFβ) receptor I (TβRI), galunisertib (LY2157299), for use in the treatment of androgenic alopecia (AGA), acting against TGFβ repressive signaling during ex vivo human HF growth cycle. Inhibition by galunisertib translates into improved proliferation and β-catenin levels in the hair bulb epithelial compartment and delayed catagen onset. Moreover, topical treatment with galunisertib in a depilated mouse model, prolongs the hair cycle anagen stage, enhancing hair growth without apparent side effects. Histological studies further confirm that galunisertib treatment improves the proliferation of hair germ progenitor cells. The present invention also refers to a pharmaceutical composition for use in the treatment of androgenic alopecia comprising galunisertib and other compounds selected from the group consisting of an excipient, a diluent, a stabilizing agent, a carrier, a surfactant, an antioxidant and a buffering agent, and combinations thereof. The present invention further refers to new routes of administration of the said composition in the said use (treatment of AGA), which can be topical, dermal, transdermal and subcutaneous. The use, compositions and routes of administration disclosed in the present invention may be advantageously employed for example as a topical composition for pharmacological intervention for use in the treatment of AGA, or any other types of alopecia or hair loss.